Published in Int J Cancer on November 14, 2013
RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines. Int J Clin Exp Pathol (2014) 0.76
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. Oncotarget (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol (2004) 3.94
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res (1985) 2.02
High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene (2007) 1.83
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79
Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res (2002) 1.51
Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev (2011) 1.46
The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res (2007) 1.45
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst) (2010) 1.30
Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol (1996) 1.29
In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis (1996) 1.11
Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther (2006) 1.01
Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair. Cell Cycle (2011) 1.00
Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) (2005) 0.99
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res (2011) 0.93
Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Mol Mutagen (2010) 0.92
DNA repair and replication proteins as prognostic markers in melanoma. Histopathology (2012) 0.90
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem (2011) 0.88
Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol Cancer Ther (2003) 0.86
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol (2009) 0.85
Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res (1998) 0.84
Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs (2000) 0.83
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys (2007) 3.65
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol (2013) 2.22
A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol Cell (2005) 2.15
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta. EMBO J (2006) 1.89
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev (2005) 1.83
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. J Clin Pathol (2012) 1.77
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res (2010) 1.64
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res (2002) 1.51
Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer (2008) 1.50
XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol (2009) 1.50
Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev (2011) 1.46
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2006) 1.45
Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J (2009) 1.41
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol (2004) 1.40
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res (2005) 1.37
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev (2005) 1.36
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 1.28
Human SNM1A suppresses the DNA repair defects of yeast pso2 mutants. DNA Repair (Amst) (2007) 1.27
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Evaluation of a novel Conjunctive Exploratory Navigation Interface for consumer health information: a crowdsourced comparative study. J Med Internet Res (2014) 1.15
DNA interstrand cross-link repair in the Saccharomyces cerevisiae cell cycle: overlapping roles for PSO2 (SNM1) with MutS factors and EXO1 during S phase. Mol Cell Biol (2005) 1.14
Preventing heat-related morbidity and mortality: new approaches in a changing climate. Maturitas (2009) 1.14
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol (2005) 1.12
Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol (2009) 1.11
DNA interstrand cross-link repair in Saccharomyces cerevisiae. FEMS Microbiol Rev (2006) 1.11
Pathways for Holliday junction processing during homologous recombination in Saccharomyces cerevisiae. Mol Cell Biol (2011) 1.09
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther (2003) 1.07
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol (2008) 1.06
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res (2006) 1.06
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res (2010) 1.05
A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol (2013) 1.04
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res (2012) 1.03
The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res (2005) 1.02
Characterization of the human SNM1A and SNM1B/Apollo DNA repair exonucleases. J Biol Chem (2012) 1.00
Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair. Cell Cycle (2011) 1.00
DNA repair pathways in drug resistance in melanoma. Anticancer Drugs (2004) 0.98
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol (2012) 0.98
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
The SNM1/Pso2 family of ICL repair nucleases: from yeast to man. Environ Mol Mutagen (2010) 0.97
Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer (2003) 0.97
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest (2003) 0.96
Components of a Fanconi-like pathway control Pso2-independent DNA interstrand crosslink repair in yeast. PLoS Genet (2012) 0.93
Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links. Mol Cell Biol (2003) 0.93
MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res (2011) 0.93
Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol (2012) 0.93
Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res (2009) 0.91
Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms. Int J Oncol (2013) 0.91
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol (2012) 0.90
Biological and therapeutic relevance of nonreplicative DNA polymerases to cancer. Antioxid Redox Signal (2012) 0.89
Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Lett (2003) 0.89
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol (2006) 0.89
The Ino80 chromatin-remodeling complex restores chromatin structure during UV DNA damage repair. J Cell Biol (2010) 0.89
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res (2012) 0.89
Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol Cancer Ther (2003) 0.88
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma Res (2004) 0.88
Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2009) 0.88
The UK burden of injury study - a protocol. [National Research Register number: M0044160889]. BMC Public Health (2007) 0.88
Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound. Ultrasound Med Biol (2004) 0.86
Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) (2014) 0.85
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res (2010) 0.85
Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. Eur J Cancer (2008) 0.83
Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species. Cancer Chemother Pharmacol (2007) 0.83
A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin. Blood (2008) 0.83
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol (2012) 0.83
Human HEL308 localizes to damaged replication forks and unwinds lagging strand structures. J Biol Chem (2011) 0.83
High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol (2002) 0.83
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol Res (2009) 0.82
DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145. Mol Cancer Ther (2007) 0.82
Inflammatory and redox status of ponies with a history of pasture-associated laminitis. Vet Immunol Immunopathol (2008) 0.82
The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts. Cancer Chemother Pharmacol (2012) 0.81
Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin. Int J Cancer (2014) 0.81
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res (2015) 0.81
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med (2012) 0.80
Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer Lett (2007) 0.80
Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta. Carcinogenesis (2012) 0.80
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. Oncol Rep (2013) 0.80